DEB-TACE

PROCEDURE15 trials

Sponsors

Boston Scientific Corporation, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Surefire Medical, Inc., Air Force Military Medical University, China, Zhejiang University

Conditions

Carcinoma, HepatocellularCholangiocarcinoma Non-resectableDEB-TACEHCCHCC - Hepatocellular CarcinomaHepatocellular CarcinomaHepatocellular Carcinoma (HCC)Hepatocellular Carcinoma Non-resectable

Phase 2

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Zhejiang UniversityHepatocellular Carcinoma

Start: 2019-11-20End: 2022-12-30Updated: 2022-06-09

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

RecruitingNCT04522544

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestHCC, Hepatocellular Carcinoma Non-resectable

Start: 2020-12-15End: 2027-12-31Target: 55Updated: 2026-02-18

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

RecruitingNCT06192784

Tongji HospitalCholangiocarcinoma Non-resectable

Start: 2023-12-09End: 2025-06-30Target: 36Updated: 2024-01-09

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

RecruitingNCT06397235

Second Affiliated Hospital of Guangzhou Medical UniversityHepatocellular Carcinoma Non-resectable

Start: 2024-05-01End: 2028-04-30Target: 130Updated: 2025-02-20

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

RecruitingNCT07157969

Peking Union Medical College HospitalHCC - Hepatocellular Carcinoma

Start: 2025-02-19End: 2027-06-30Target: 300Updated: 2025-12-01

Phase 3

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

TerminatedNCT02460991

Boston Scientific CorporationHepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma

Start: 2015-11-30End: 2017-06-05Updated: 2021-02-12

Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma

IRCCS Azienda Ospedaliero-Universitaria di BolognaCarcinoma, Hepatocellular

Start: 2019-12-04End: 2022-04-30Target: 154Updated: 2021-03-19

DEB-TACE vs cTACE in HCC After TIPS

RecruitingNCT07322848

First Affiliated Hospital, Sun Yat-Sen UniversitycTACE, DEB-TACE, Hepatocellular Carcinoma (HCC) +2

Start: 2025-12-01End: 2029-12-31Target: 206Updated: 2026-01-07

Phase 4

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

RecruitingNCT06353126

RenJi HospitalLiver Cancer

Start: 2024-10-16End: 2027-07-01Target: 40Updated: 2024-10-18

Unknown Phase

Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC

CompletedNCT02670122

Instituto de Investigación Sanitaria de la Fundación Jiménez DíazHepatocellular Carcinoma

Start: 2015-03-31End: 2018-11-30Updated: 2021-03-30

DEB-TACE for Hepatocellular Carcinoma

TerminatedNCT02748161

Surefire Medical, Inc.Hepatocellular Carcinoma

Start: 2015-08-31End: 2018-06-15Target: 170Updated: 2018-06-21

Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)

Air Force Military Medical University, ChinaHepatocellular Carcinoma

Start: 2020-09-15End: 2022-06-15Target: 344Updated: 2020-02-05

Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;

Beijing Tsinghua Chang Gung HospitalHepatocellular Carcinoma

Start: 2020-03-18End: 2025-12-31Target: 226Updated: 2021-02-04

PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer

Tongji HospitalHepatocellular Carcinoma

Start: 2021-12-01End: 2025-06-30Target: 200Updated: 2023-12-19

DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial

RecruitingNCT05788835

Start: 2023-03-07End: 2026-06-30Target: 220Updated: 2023-03-29

Related Papers

Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial

Hepatology Communications2023-02-0918 citations

Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma.

2020-03-1919 citations